New drug wraps Cancer-Fighting payload in liposomes to target tough tumors
NCT ID NCT06526819
First seen Mar 26, 2026 · Last updated Jun 24, 2026 · Updated 17 times
Summary
This study tests a new drug called SMP-3124LP, which is a standard cancer drug wrapped in a fatty bubble (liposome) to help it work better. It is for adults with advanced solid tumors that have not responded to other treatments. The trial has two parts: first, finding a safe dose, and second, seeing if the drug shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kyoto University Hospital
RECRUITINGKyoto, 606-8507, Japan
Contact Email: •••••@•••••
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
National Cancer Center Hospital East
RECRUITINGKashiwa-shi, 277-8577, Japan
Contact Email: •••••@•••••
-
Northwestern Medicine Cancer Center
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
Contact Email: •••••@•••••
-
Sarah Cannon Research Institute at HealthOne
RECRUITINGDenver, Colorado, 80218, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Washington
RECRUITINGSeattle, Washington, 98105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Vanderbilt-Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SMP-3124LP (a liposomal formulation of the drug SMP-3124)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial with only 120 participants, so the drug may not prove effective or safe enough for wider use. Side effects are unknown and could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.